Medscape | CLL Trial Stopped as Ibrutinib Shows Significant Benefits Medscape The only agent so far to have shown an early definitive overall survival benefit in CLL is rituximab (Rituxan, Genentech/Roche), and hence a combination of ibrutinib with rituximab is very appealing — and trials of this combination are in progress ... J&J's Imbruvica tops Arzerra in phase III trial |
